Unpolished Thai Rice Prevents Aberrant Crypt Foci Formation through the Invovement of β-catenin and COX-2 Expression in Azoxymethane-Treated Rats

  • Published : 2016.07.01


Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world, with chronic inflammation and diet as major causes in its development. Chemopreventive effects of natural dietary products have been the focus of studies for prevention over the past decade. This study was conducted to determine the effects of unpolished Thai rice during precancerous stage through the involvement of ${\beta}$-catenin, cyclooxygenase-2 (COX-2) expression and inflammatory cytokines focusing on azoxymethane (AOM)-induced aberrant crypt foci (ACF)-related to CRC. Male Sprague Dawley rats received two injections of AOM (15 mg/kg body weight) at weeks 4 and 5 while rats were treated with 20% or 70% unpolished Thai rice. The rats were sacrificed at week 38 and the colons removed for aberrant crypt foci (ACF) identification. Histopathologic changes, immunohistochemical analysis of ${\beta}$-catenin and COX-2 expression, and cytokine expression of proinflammatory and anti-inflammatory markers were determined. The administration of unpolished Thai rice significantly and dose dependently decreased the total number of ACF and the percentages of ACF with high-grade dysplasia. Interestingly, unpolished Thai rice suppressed the expression of ${\beta}$-catenin and COX-2. In addition, it also altered proinflammatory (IL-6 and IFN-${\gamma}$) and anti-inflammatory (IL- 10) markers. The results suggested that unpolished Thai rice may provide a promising dietary intake for prevention during precancerous stage of CRC development, through the involvement of ${\beta}$-catenin and COX-2 expression, and also modulate inflammatory cytokines-related to CRC.


Supported by : Mahidol University


  1. Ashokkumar P, Sudhandiran G (2011). Luteolin inhibits cell proliferation during azoxymethane-induced experimental colon carcinogenesis via Wnt/${\beta}$-catenin pathway. Invest New Drugs, 29, 273-84.
  2. Bird RP (1987). Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett, 37, 147-51.
  3. Candela M, Turroni S, Biagi E, et al (2014). Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol, 20, 908-22.
  4. Chan A, Giovannucci E (2010). Primary prevention of colorectal cancer. Gastroenterol, 138, 2029-43.
  5. De Waal Malefyt R, Abrams J, Bennett B, et al (1991). Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an auto-regulatory role of IL-10 produced by monocytes. J Exp Med, 174, 1209-20.
  6. Fenoglio-Preiser C, Noffsinger A (1999). Aberrant crypt foci: A review. Toxicol Pathol, 27, 632-42.
  7. Fredericks E, Dealtry G, Roux S (2015). Molecular aspects of colorectal carcinogenesis: A review. J Cancer Biol Res, 3, 1057-64.
  8. Greten FR, Eckmann L, Greten T, et al (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitisassociated cancer. Cell, 118, 285-96.
  9. Hegazy RA, Hegazy AA, Abdel-Aziz HR, et al (2013). Expression of ${\beta}$-catenin and cyclooxygenase 2 in colorectal carcinoma: An immunohistochemical study. Universal J Med Sci, 1, 72-7.
  10. Hong SK, Gul YA, Ithnin H, et al (2004). Expression of betacatenin, COX-2 and iNOS in colorectal cancer: relevance of COX-2 and iNOS inhibitors for treatment in Malaysia. Asian J Surg, 27, 10-7.
  11. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  12. Kantola T, Klintrup K, Vayrynen J, et al (2012). Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer, 107, 1729-36.
  13. Katyama M, Yoshimi N, Yamada Y, et al (2002). Preventive effect of fermented brown rice and rice bran against colon carcinogenesis in male F344 rats. Oncol Rep, 9, 817-22.
  14. Kazem A, Sayed K, Kerm Y (2014). Prognostic significance of COX-2 and ${\beta}$-catenin in colorectal carcinoma. Alex J Med, 50, 211-20.
  15. Knupfer H, Preiss R (2010). Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int J Colorectal Dis, 25, 135-40.
  16. Kraus S, Arber N (2009). Inflammation and colorectal cancer. Curr Opin Pharmacol, 9, 405-10.
  17. Luceri C, Caademi G, Sanna A, et al (2002). Red wine and black tea polyphenols modulate the expression of cyclooxygenase-2, inducible nitric oxide synthase and glutathione-related enzymes in azoxymethane-induced F344 rat colon tumors. J Nutr, 132, 1376-9.
  18. Mori H, Hata K, Yamada Y, et al (2005). Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem Biol Interact, 155, 1-9.
  19. Nishino H, Satomi Y, Tokuda H, et al (2007). Cancer control by phytochemicals. Curr Pharm Des, 13, 3394-9.
  20. Nunez F, Bravo S, Ceuzat F, et al (2011). Wnt/${\beta}$-catenin signaling enhances cyclooxygenenase-2 (COX-2) transcriptional activity in gastric cancer cells. PLoS ONE, 6, 1-10.
  21. Oving IM, Clevers HC (2002). Molecular causes of colon cancer. Eur J Clin Invest, 32, 448-57.
  22. Pan MH, Lai CS, Wu JC, et al (2011). Molecular mechanisms for chemoprevention of colorectal cancer by natural dietary compounds. Mol Nutr Food Res, 55, 32-45.
  23. Pandurangan AK (2013). Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev, 14, 2201-5.
  24. Pandurangan AK, Esa NM (2013). Dietary non-nutritive factors in targeting of regulatory molecules in colorectal cancer: an update. Asian Pac J Cancer Prev, 14, 5543-52.
  25. Sillars-Hardebol A, Carvalho B, De Wit M, et al (2010). Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol, 31, 89-96.
  26. Soria J-C, Moon C, Kemp BL, et al (2003). Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Can Res, 9, 1785-91.
  27. Sturlan S, Oberhuber G, Beinhauer B, et al (2001). Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis, 22, 665-71.
  28. Surh Y (2003). Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer, 3, 768-80.
  29. Suwannalert P, Rattanachitthawat S (2011). High levels of phytophenolics and antioxidant activities in Oryza sativa - unpolished Thai rice strain of Leum Phua. Trop J Pharm Res, 10, 431-6.
  30. Takahashi M, Fukuda K, Sugimura T, et al (1998). ${\beta}$-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res, 58, 42-6.
  31. Takayama T, Katsuki S, Takahashi Y, et al (1998). Aberrant crypt foci of the colon as precacerous of adenoma and cancer. N Engl J Med, 339, 1277-84.
  32. Tammasakchai A, Reungpatthanaphong S, Chaiyasut C, et al (2012). Red strain Oryza sativa - unpolished Thai rice prevents oxidative stress and colorectal aberrant crypt foci formation in rats. Asian Pac J Cancer Prev, 13, 1929-33.
  33. Tantamango YM, Knutsen SF, Beeson WL, et al (2011). Foods and food groups associated with the incidence of colorectal polyps: the adventist health study. Nutr Cancer, 63, 565-72.
  34. Toiyama Y, Miki C, Inoue Y, et al (2010). Loss of tissue expression of interleukin-10 promotes the disease progression of colorectal carcinoma. Surg Today, 40, 46-53.
  35. Visco C, Vassilakopoulos T, Kliche K, et al (2004). Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma, 45, 2085-92.
  36. Wargovich MJ, Brown VR, Morris J (2010). Aberrant crypt foci: the case for inclusion as a biomarker for colon cancer. Cancers, 2, 1705-16.
  37. Xiao H, Hao XP, Simi B, et al (2008). Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats. Carcinogenesis, 29, 113-9.
  38. Zhao S, Wu D, Wu P, et al (2015). Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis. PLoS ONE, 10, 1-15.